Summary
The effects of two beta-blocking drugs on endogenous insulin secretion and insulin sensitivity were investigated in a double blind cross-over study in 13 hypertensive patients. The patients were randomly allocated to each of three 2-week treatment periods with propranolol 80 mg b.i.d., atenolol 50 mg b.i.d. and placebo b.i.d. Endogenous insulin secretion was assessed by measuring serum insulin and C-peptide before and 6 min after iv administration of glucagon; insulin sensitivity was determined by measuring insulin binding to erythrocytes, and as the glucose disappearance rate (KITT) after i.v. insulin. Fasting concentrations of serum free fatty acids (S-FFA) and plasma gastric inhibitory polypeptide (P-GIP) were also recorded during the three study periods. Both propranolol and atenolol reduced blood pressure, heart rate and S-FFA concentrations compared to placebo, and all patients showed measurable plasma concentrations of propranolol and atenolol. The results can be considered representative, therefore, of clinical beta-blockade. The two drugs did not significantly influence the fasting blood glucose level. There was an increase in fasting and glucagon-stimulated serum C-peptide concentration during propranolol therapy compared with placebo (p=0.037 and p=0.030, respectively), although this was not reflected by a significant change in serum insulin. Propranolol and atenolol did not significantly influence insulin binding to erythrocytes, but they clearly reduced the glucose disappearance rate KITT was compared to placebo (p=0.0036 and p=0.0003, respectively). The findings support the view that beta-blocking drugs can influence glucose metabolism by mechanisms other than inhibition of endogenous insulin secretion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Editorial (1980) Antihypertensive drugs, plasma lipids, and coronary disease. Lancet 2: 19–20
Groop L, Tötterman KJ, Harno K, Gordin A (1982) Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus. Acta Med Scand 211: 7–12
Groop L, Tötterman KJ, Harno K, Gordin A (1983) Influence of beta-blocking drugs on glucose metabolism in hypertensive, non-diabetic patients. Acta Med Scand 213: 9–14
William-Olsson T, Fellenius E, Smith K, Björntorp P (1979) Differences in metabolic responses to β-adrenergic stimulation after propranolol and metoprolol administration. Acta Med Scand 205: 201–206
Robertson RP, Porte D Jr (1973) The glucose receptor. A defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor. J Clin Invest 52: 870–876
Cerasi E, Luft R, Efendic S (1972) Effect of adrenergic blocking agents on insulin response to glucose infusion in man. Acta Endocrinol 69: 335–346
Day JL, Simpson N, Metcalfe J, Page RL (1979) Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J 1: 77–80
Ekberg G, Hansen B-G (1977) Glucose tolerance and insulin release in hypertensive patients treated with the cardioselective β-receptor blocking agent metoprolol. Acta Med Scand 202: 393–397
Groop L, Tötterman KJ (1982) Propranolol does not inhibit sulfonylurea-stimulated insulin secretion in patients with non-insulin dependent diabetes mellitus. Acta Endocrinol 100: 410–415
Tötterman KJ, Groop LC (1982) No effect of propranolol and metoprolol on tolbutamide-stimulated insulin secretion in hypertensive diabetic and non-diabetic patients. Ann Clin Res 14: 190–193
Lundqvist I (1972) Interactions of amines and adrenergic blocking agents with blood glucose regulation. Eur J Pharmacol 18: 213–224
Scholhammer C, Felig P, Hendler RG (1971) Propranolol hypoglycemia: increased peripheral effectiveness of insulin. Clin Res 19: 736
Faber OK, Binder C (1977) C-peptide response to glucagon. A test for the residual beta-cell function. Diabetes 26: 605–610
Beck-Nielsen H, Pedersen O (1978) Insulin receptors on monocytes of young healthy persons correlated with glucose tolerance and insulin sensitivity. Diabetologia 14: 159–163
Cheng JS, Kalant N (1970) Effects of insulin and growth hormone on the flux rates of plasma glucose and plasma free fatty acids in man. J Clin Endocrinol 31: 647–653
Herbert V, Lau K-S, Gottlieb CW, Bleicher SI (1965) Coated charoal immunoassay of insulin. J Clin Endocrinol 25: 1375–1384
Heding LG, Kasperska-Czyzykowa T (1980) C-peptide and proinsulin after oral glucose. Acta Med Scand [Suppl] 639: 33–36
Burhol PG, Jorde R, Waldum HL (1980) Radioimmunoassay of plasma gastric inhibitory polypeptide (GIP), release of GIP after a test meal and duodenal infusion of bile, and immunoreactive plasma GIP components in man. Digestion 20: 336–345
Novak M (1965) Colorimetric ultramicromethod for the determination of free fatty acids. J Lipid Res 6: 431–433
Pedersen O, Beck-Nielsen H, Heding L (1980) Increased insulin receptors after exercise in patients with insulin dependent diabetes mellitus. N Engl J Med 302: 886–892
Gambhir KK, Archer JA, Bradley CJ (1978) Characteristics of human erythrocyte insulin receptors. Diabetes 27: 701–708
Di Salle E, Baker KM, Bareggi SR, Watkins WD, Chidsey CA, Frigerio A, Morselli PL (1973) A sensitive gas chromatographic method for the determination of propranolol in human plasma. J Chromatogr 84: 347–353
Dixon WJ (1981) BMPD statistical software. University of California Press, Berkeley
Allison SP, Chamberlain MJ, Miller JE, Ferguson R, Gillett AP, Bemand BV, Saunders RA (1969) Effect of propranolol on blood sugar, insulin and free fatty acids. Diabetologia 5: 339–342
Wright AD, Barber SG, Kendall MJ, Poole PH (1979) Beta-adrenoceptor-blocking drugs and blood sugar control in diabetes mellitus. Br Med J 1: 159–161
Stoll RW, Touber JL, Menaham LA, Williams RH (1970) Clearance of porcine insulin, proinsulin and connecting peptide by the isolated rat liver. Proc Soc Exp Biol Med 111: 894–896
Faber OK, Hagen C, Binder C, Markussen J, Naithani VK, Blix PM, Kuzyua H, Horwitz DL, Rubenstein AH, Rossing N (1978a) Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest 62: 197–203
Dupre J, Ross S, Watson D, Brown JC (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol 37: 826–828
Creutzfeld W, Ebert R (1977) Release of gastric inhibitory polypeptide (GIP) to a test meal under normal and pathological conditions in man. In: Bajaj IS (ed) Diabetes, Excerpta Medica, Amsterdam
Spanheimer RG, Bar RS, Ginsberg BH, Peacock ML, Martino I (1982) Comparison of insulin binding to cells of fed and fasted obese patients: results in erythrocytes and monocytes. J Clin Endocrinol 54: 40–47
Abramson EA, Arky RA (1968) Role of beta-adrenergic receptors in counterregulation to insulin-induced hypoglycemia. Diabetes 17: 141–146
Cherrington AD, Assimacopoulos FD, Harper SC, Corbin JD, Park CR, Exton JH (1976) Studies on the α-adrenergic activation on hepatic glucose output. J Biol Chem 251: 5209–5218
Pinter EJ, Pattee CJ, Peterfy G, Cleghorn JM (1967) Metabolic effects of autonomic blockade. Lancet 2: 101
Lebrec D, Novel O, Corbic M, Benhamov J-P (1980) Propranolol-a medical treatment for portal hypertension? Lancet 2: 180–182
Deacon SP, Barnett D (1976) Comparison of atenolol and propranolol during insulin-induced hypoglycemia. Br Med J 2: 272–273
Lager I, Blohmé G, Smith U (1979) Effect of cardioselective and non-selective β-blockade on the hypoglycemic response in insulin-dependent diabetes. Lancet 1: 458–462
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tötterman, K., Groop, L., Groop, P.H. et al. Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients. Eur J Clin Pharmacol 26, 13–17 (1984). https://doi.org/10.1007/BF00546701
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00546701